Loading…
Traws Pharma, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in TRAW.
▼ -99.3% over 5Y.
today you would have $5.88▼ -99.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 13 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.13 | $8.88 | $18.75 | $16.25 | $63.75 | $176.25 | $142.50 | $791.25 | $8,437.50 | $12,768.75 | $54,000.00 | $185,062.50 | $645,750.00 | |
| P/E | — | 1.4x | — | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MBAIMBody AI Ltd. | $6.58 | 1.4x | 13.4x | — | — | $9.05M |
| IMNNImunon, Inc. | $1.60 | — | 3.9x | — | -429.72% | $8.98M |
| IMRNImmuron Ltd | $1.15 | — | 1.0x | — | -39.68% | $9.28M |
| XBIOXenetic Biosciences, Inc. | $3.98 | — |
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| P/S | 52.3x | 6.1x | 209.6x | 84.0x | 60.3x | 235.8x | 481.4x | 29.1x | 10.1x | 36.1x | 2.8x | 2.3x | 89.3x | 52.3x |
| P/B | 2.9x | — | — | 1.8x | 0.5x | 1.2x | 18.0x | 5.5x | 2.3x | — | 3.6x | 2.6x | 3.1x | 3.1x |
| EPS | $0.82 | -$35.21 | -$22.57 | -$22.75 | -$24.00 | -$54.25 | -$558.75 | -$1,871.25 | -$15,056.25 | -$24,975.00 | -$59,287.50 | -$165,375.00 | -$344,250.00 |
| Profit margin | -3061.25% | 328.67% | -73682.74% | -8384.07% | -8391.15% | -7151.77% | -10890.48% | -985.02% | -1675.33% | -3061.25% | -354.62% | -209.31% | -7960.25% | -1315.86% |
| ROE | -212.67% | — | — | -177.55% | -66.99% | -35.05% | -407.40% | -185.79% | -381.90% | — | -457.69% | -239.55% | -279.95% | -77.78% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 1.2x |
| — |
| -47.04% |
| $9.33M |
| NDRAENDRA Life Sciences Inc. | $5.80 | — | 1.4x | — | -152.04% | $8.7M |
| EVGNEvogene Ltd. | $0.55 | — | — | — | -182.75% | $8.68M |